title: Evaluation of the new INNOVANCE® PFA P2Y cartridge in patients with impaired primary haemostasis.
abstract: Recently, the INNOVANCE® PFA P2Y (P2Y) cartridge of the PFA-100® system (Siemens Healthcare Diagnostics, Marburg, Germany) has been developed for the monitoring of adenosine diphosphate (ADP) P2Y(12) receptor inhibition in patients under dual antiplatelet therapy. The aim of this study was to evaluate the influence of pre-existing defects in primary haemostasis on the P2Y cartridge independent from specific antiplatelet medication. Therefore, the closure time (CT) of the P2Y cartridge was measured in a cohort of 176 patients with assumed bleeding disorders and compared with the results of established methods for the assessment of primary haemostasis. Von Willebrand disease (VWD) was found in 25 patients (14%). The detection rate of the P2Y cartridge regarding VWD was 64% and lower compared to the two conventional cartridges (collagen/epinephrine cartridge, CEPI, 80%; collagen/ADP cartridge, CADP, 76%). In the subgroup of VWD patients with VWF:RCo < 60 IU/dL (n = 22), the correlation analysis and the inter-rater agreement revealed only limited accordance with the two established cartridges. The correlation with the CADP cartridge (C(r) = 0.767, R(2) = 0.461; Kappa = 0.41) was higher than the correlation with the CEPI cartridge. Except for severe forms, platelet function disorders (9 patients, 5%) did not prolong the CT of the P2Y cartridge. Interestingly, the P2Y cartridge was less interference-prone to unspecific medications (23 patients, 13%). As the main conclusion, it must be taken into account that low von Willebrand factor activity can significantly influence the CTs of the P2Y cartridge when using it for the monitoring of antiplatelet therapy.
authors.affiliation: Institut fuer Klinische Biochemie und Pathobiochemie-Zentrallabor, Universitaetsklinikum Wuerzburg, Wuerzburg, Germany. j.koessler@medizin.uni-wuerzburg.de
authors.forename: Juergen
authors.initials: J
authors.lastname: Koessler
authors.forename: Martin
authors.initials: M
authors.lastname: Ehrenschwender
authors.forename: Anna
authors.initials: A
authors.lastname: Kobsar
authors.forename: Kirsten
authors.initials: K
authors.lastname: Brunner
mesh_terms: D000244:Adenosine Diphosphate / Q000378:metabolism; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001780:Blood Coagulation Tests / Q000295:instrumentation* / Q000592:standards*; D003894:Deamino Arginine Vasopressin / Q000494:pharmacology; D005260:Female; D006487:Hemostasis; D006801:Humans; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D058921:Purinergic P2Y Receptor Antagonists / Q000494:pharmacology; D058470:Receptors, Purinergic P2Y / Q000097:blood*; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D014842:von Willebrand Diseases / Q000097:blood* / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D014841:von Willebrand Factor / Q000378:metabolism
chemical_list: D010975:Platelet Aggregation Inhibitors; D058921:Purinergic P2Y Receptor Antagonists; D058470:Receptors, Purinergic P2Y; D014841:von Willebrand Factor; D000244:Adenosine Diphosphate; D003894:Deamino Arginine Vasopressin